Marfan syndrome is a dubious disease in the field of autoimmune and rheumatic immunity, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardized clinical care are critical to improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory tests and pathological activation.
The platform can assist in matching domestic and foreign authoritative experts and teams to provide accurate diagnosis and treatment plans. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved. Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely schemes according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of Marfan syndrome. The platform serves the China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: Remote pre-diagnosis: by the team of experts to review the medical history, clear diagnostic directions and medical advice on: 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.